Efficacy and safety of cladribine: Subcutaneous versus intravenous administration in hairy cell leukemia

被引：0
|
作者：
Yakout, T. [1 ]
Mosaad, G. [2 ]
Namour, A. [2 ]
Malek, R. [3 ]
Khorshid, O. [2 ]
机构：
[1] Cairo Oncol Ctr, Cairo, Egypt
[2] Natl Canc Inst, Cairo, Egypt
[3] Cairo Univ, Fac Med, Cairo, Egypt
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3652
引用
收藏
页码：S852 / S852
页数：1
相关论文
共 50 条
  • [31] Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine)
    Füreder, W
    Weltermann, A
    Chott, A
    Gisslinger, H
    Valent, P
    Jäger, U
    Geissler, K
    Lechner, K
    WIENER KLINISCHE WOCHENSCHRIFT, 1999, 111 (24) : 1027 - 1030
  • [32] Potential curability of cladribine in selected patients with hairy cell leukemia
    Sigal, D.
    Sharpe, R. W.
    Burian, C.
    Saven, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Safety of subcutaneous versus intravenous ceftriaxone administration in older patients: A retrospective study
    Pardo, Ines
    Pierre-Jean, Morgane
    Bouzille, Guillaume
    Fauchon, Heloise
    Corvol, Aline
    Prud'homm, Joaquim
    Somme, Dominique
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2024, 72 (04) : 1060 - 1069
  • [34] Serum concentration and safety of intravenous drip versus subcutaneous administration of carboplatin in dogs
    Iwano, Masataka
    Sadahiro, Kohei
    Maruo, Takuya
    Kawarai, Shinpei
    Kayanuma, Hideki
    Orito, Kensuke
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2021, 83 (05): : 775 - 779
  • [35] 2-CDA in the treatment of hairy-cell leukaemia: intravenous vs subcutaneous administration
    Sperb, RA
    von Rohr, A
    Ratschiller, D
    Bacchi, M
    Tichelli, A
    Hess, U
    Cerny, T
    Tobler, A
    Betticher, DC
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1998, 128 (42) : 1593 - 1597
  • [36] PRIMARY PEGFILGRASTIM PROPHYLAXIS VERSUS FILGRASTIM GIVEN "ON DEMAND" FOR CLADRIBINE - INDUCED NEUTROPENIA IN HAIRY CELL LEUKEMIA
    Inbar, M.
    Herishanu, Y.
    Goldschmidt, N.
    Bairey, O.
    Yuklea, M.
    Shvidel, L.
    Fineman, R.
    Aviv, A.
    Ruchlemr, R.
    Braester, A.
    Najib, D.
    Rouvio, O.
    Shaulov, A.
    Greenbaum, U.
    Polliack, A.
    Tadmor, T.
    HAEMATOLOGICA, 2017, 102 : 425 - 425
  • [37] Randomized comparison of weekly administration and daily courses of cladribine in patients with hairy cell leukemia updated results.
    Robak, T
    Kasznicki, M
    Gora-Tybor, J
    Dwilewicz-Trojaczek, J
    Dmoszynska, A
    Wojtaszko, M
    Zdziarska, B
    Calbecka, M
    Hellmann, A
    Stella-Holowiecka, B
    Sulek, K
    Skotnicki, A
    Zawilska, K
    Kloczko, J
    Warzocha, K
    Konopka, L
    BLOOD, 2004, 104 (11) : 948A - 948A
  • [38] IgA vasculitis revealing hairy cell leukemia relapse treated by cladribine
    Audemard, Alexandra
    Crochette, Romain
    Salauen, Veronique
    Comoz, Francois
    Ficheux, Maxence
    PRESSE MEDICALE, 2014, 43 (03): : 321 - 323
  • [39] LOW-DOSE CLADRIBINE FOR SYMPTOMATIC HAIRY-CELL LEUKEMIA
    JULIUSSON, G
    LENKEI, R
    TJORNFJORD, G
    HELDAL, D
    LILIEMARK, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (03) : 637 - 639
  • [40] Phase II Clinical Study of Cladribine in the Treatment of Hairy Cell Leukemia
    Takashi Machii
    Takaaki Chou
    Muneou Suzuki
    Yokiko Ohe
    Shuichi Katagiri
    Katagiri Kitano
    Yoshihide Fujiyama
    Tooru Izumi
    Chihiro Shimazaki
    Koji Nanba
    Yasuo Ohashi
    Teruo Kitani
    International Journal of Hematology, 2005, 82 : 230 - 235
12345